Has everyone read BTA's US corporate presentation - it's really well put together- very exciting indeed -http://www.biota.com.au/uploaded/154/1021614_681001uscorporatepresenta.pdf
love this section -
Stockpile market: growth driver
The stockpile is ~US$8B globally and has been built over 4/5 years
Stockpile initiated in 2004 by World Health Organization (WHO)
Approx 60 countries intend to/or carry stockpiles
WHO recommended the initial size of national stockpiles
One course for 25% of population
U.S. stockpile has not achieved that target currently ~22%; c.f. France 33%,
UK 35%(intention to 50%), Australia 55%.
WHO recommends increasing percentage coverage of the population as
capacity/funding permits
Relenzas percentage of the stockpile is increasing due to:
Drug interactions and side effects with oseltamivir
Concerns of oseltamivir resistance
To date, 28 H1N1 pandemic viruses resistant to oseltamivir have been detected (now 206 )
and characterized worldwide**
All of these viruses show the same H275Y mutation that confers resistance to
oseltamivir, but not to zanamivir
Rebalancing from 15:85 Relenza:Tamiflu towards 50:50
*
- Forums
- ASX - By Stock
- us corporate presentation is excellent
Has everyone read BTA's US corporate presentation - it's really...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)